Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor.
Immunization of DBA/1 mice with type II collagen within complete Freund's adjuvant leads to arthritis, lasting more than 3 months. Injection of anti-tumour necrosis factor (TNF) IgG, 2 and 3 weeks after immunization prevented the development of arthritis in the following months. This treatment had no effect when started 2 months after induction of the disease. A soluble form of the human recombinant TNF receptor type-beta (rsTNFR-beta), continuously infused at a rate of 20 micrograms/day during the second and third week after immunization, also had a long-term protective effect. Anti-TNF antibody had no effect upon the production of anti-type II collagen antibodies. These results indicate that TNF is critically involved in an early phase of this arthritis.
Piguet
P F
PF
Department of Pathology, University of Geneva, Switzerland.
Grau
G E
GE
Vesin
C
C
Loetscher
H
H
Gentz
R
R
Lesslauer
W
W
D000818:Animals; D001168:Arthritis / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control; D001323:Autoantibodies / Q000096:biosynthesis; D003094:Collagen / Q000276:immunology*; D005528:Foot / Q000473:pathology; D007074:Immunoglobulin G / Q000276:immunology; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D012333:RNA, Messenger / Q000032:analysis; D011956:Receptors, Cell Surface / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000276:immunology*
D001323:Autoantibodies; D007074:Immunoglobulin G; D012333:RNA, Messenger; D011956:Receptors, Cell Surface; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D003094:Collagen